For these reasons, the pharmaceutical development of PTP1B inhibitors may serve as a novel type of insulin sensitizer in the management of type 2 diabetes and other cardiovascular syndrome or obesity [117]. The gene discussed is INS; the disease is type 2 diabetes mellitus.